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Abstract
It is well known that the ubiquitin-proteasome system is activated in response to skeletal
muscle wasting and functions to degrade contractile proteins. The loss of these proteins
inevitably reduces skeletal muscle size (i.e., quantity). However, it is currently unknown
whether activation of this pathway also affects function by impairing the muscle’s intrinsic
ability to produce force (i.e., quality). Therefore, the purpose of this study was twofold, (1)
document how the ubiquitin-proteasome system responds to denervation and (2) identify
the physiological consequences of these changes. To induce soleus muscle atrophy,
C57BL6 mice underwent tibial nerve transection of the left hindlimb for 7 or 14 days (n = 6–8
per group). At these time points, content of several proteins within the ubiquitin-proteasome
system were determined via Western blot, while ex vivo whole muscle contractility was spe-
cifically analyzed at day 14. Denervation temporarily increased several key proteins within
the ubiquitin-proteasome system, including the E3 ligase MuRF1 and the proteasome sub-
units 19S, α7 and β5. These changes were accompanied by reductions in absolute peak
force and power, which were offset when expressed relative to physiological cross-sectional
area. Contrary to peak force, absolute and relative forces at submaximal stimulation fre-
quencies were significantly greater following 14 days of denervation. Taken together, these
data represent two keys findings. First, activation of the ubiquitin-proteasome system is
associated with reductions in skeletal muscle quantity rather than quality. Second, shortly
after denervation, it appears the muscle remodels to compensate for the loss of neural activ-
ity via changes in Ca2+ handling.
Introduction
Skeletal muscle atrophy can occur from a variety of stressors, which include inflammation,
mechanical unloading, metabolic stress and neural inactivity. These stressors are often a result
of clinical conditions or chronic diseases such as limb immobilization, bed rest, cachexia,
neurodegeneration and aging [1–4]. Under these situations, there is an imbalance between
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anabolic and catabolic processes with protein breakdown (i.e., proteolysis) exceeding protein
synthesis [5, 6]. Consequently, muscle mass is reduced due to the net loss of myofibrillar and
soluble proteins, organelles and cytoplasm, all of which alter muscle function either metaboli-
cally, structurally or physiologically. The increased rate of proteolysis is mediated through the
autophagy-lysosome and ubiquitin-proteasome systems [4, 7, 8], with the latter reported to be
the primary degradation pathway in skeletal muscle [9, 10].
The ubiquitin-proteasome system is a complex pathway in skeletal muscle that consists of
several components [1, 3, 11, 12]. Briefly, proteins destined for degradation are conjugated to
multiple molecules of ubiquitin by an ubiquitin ligase enzyme (E3). One of the main E3 ligases
in skeletal muscle is the muscle RING finger 1 (MuRF1) due to the fact many of its substrates
are sarcomeric proteins. Thus far, MuRF1 has been observed to ubiquitinate/interact with tro-
ponin I [13], actin [14], myosin binding protein C [15], myosin light chains 1 and 2 [15], myo-
sin heavy chain (MHC) [16, 17] and titin [18, 19]. These polyubiquitin-conjugated proteins are
then recognized and subsequently degraded into peptides by the 26S proteasome. To note, the
26S proteasome is composed of a cylindrical catalytic core particle (20S) capped at one or both
ends with 19S regulatory complexes (also known as PA700). These 20S particles consist of four
rings that contain seven subunits each. The two outer rings are composed of α-subunits (α1 to
α7) and the two inner rings of β-subunits (β1 to β7). Importantly, three of these β-subunits per-
form distinct proteolytic activities. Specifically, activity of β1 (PSMB6), β2 (PSMB7) and β5
(PSMB5) are classified as caspase-like, trypsin-like and chymotrypsin-like for their cleavage of
acidic, basic and hydrophobic amino acids, respectively.
It is well established that several components within the ubiquitin-proteasome system
increase in response to skeletal muscle wasting [20–23], and that these changes are responsible
for degrading the myofibrillar proteins MHC and actin [9, 24]. Loss of these contractile proteins
inevitably reduces skeletal muscle size (i.e., quantity). Consequently, a smaller muscle produces
less force. For instance, it has been reported that absolute force and power were both reduced in
atrophied skeletal muscle following extended periods of denervation (e.g.,one month) [25,
26]. Interestingly, contractile deficits were also observed when expressed relative to muscle size,
indicating the muscle’s intrinsic ability to contract (i.e., quality) was impaired at these later time
points [25, 26]. Although it is generally accepted loss of muscle quantity following denervation
is due to the ubiquitin-proteasome system, it is currently unknown whether muscle quality is
affected soon after an episode of increased proteolysis mediated by this pathway.
Therefore, the goals of this study were twofold, (1) document how the ubiquitin-proteasome
system responds to denervation and (2) identify the physiological consequences of these
changes. To accomplish this, we first determined when content of the ubiquitin-proteasome
system returned back to resting levels (i.e., shortly following activation) in denervated skeletal
muscle. At this point, we then performed ex vivo physiology to assess whole muscle contractil-
ity. Using this design, we were able to document how muscle function was affected soon after
protein content of the ubiquitin-proteasome system was upregulated. We hypothesized that
activation of the ubiquitin-proteasome system would be associated with reductions in skeletal
muscle quantity rather than quality. If correct, these findings would demonstrate the ubiqui-
tin-proteasome system is a fine-tuned proteolytic pathway that alters muscle size without sig-
nificantly influencing its intrinsic ability to generate force.
Methods
Animals
Adult male C57BL6 mice (6.50±0.24 months old) were used in this study. Mice were housed in
groups of no more than 4 animals per cage, supplied with food and water ad libitum, and
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maintained in a room at 20–23°C with a 12-h photoperiod. During the final procedure (i.e., Ex
vivomuscle preparation and contractility measurements), mice were anesthetized by an
intraperitoneal injection of ketamine/xylazine (100 mg/kg ketamine, 10 mg/kg xylazine), with
supplemental doses given as required. Following the completion of this procedure, mice were
euthanized by exsanguination while under anesthesia. All animal procedures were approved by
the Institutional Animal Care and Use Committee at the University of Minnesota.
Experimental design
Mice were randomly assigned to one of three groups: control, 7 day denervation or 14 day
denervation. The control group consisted of mice that did not receive any surgery, while mice
in the denervation groups underwent tibial nerve transection of the left hindlimb and were
assessed in the following 7 or 14 days. Tibial nerve transection surgery results in denervation to
the gastrocnemius, plantaris and soleus muscles, and has been reported to result in significant
atrophy [27, 28]. However, only the soleus muscle of the left hindlimb was evaluated in this
study. The soleus was specifically selected from the denervated muscles because it can be pre-
pared for ex vivo physiology due to its accessibility and size. Biochemical analyses including
Western blot, proteasome proteolytic activity and silver staining were assessed in control, 7 day
and/or 14 day groups, while fiber cross-sectional area (CSA) and whole muscle physiology
were examined in the control and 14 day groups. Post-denervation CSA and muscle physiology
were only analyzed at day 14 because the goal of this study was to assess contractility once the
ubiquitin-proteasome system returned back to baseline (i.e., following upregulation), which we
determined via Western blot analysis and proteasome proteolytic activity (See Results).
Experimental methodology
Tibial nerve transection. Tibial nerve transection was performed on the left hindlimb,
similar to that previously described [27, 29]. Briefly, while under anesthesia (2.5% isoflurane),
an incision of ~1 cm was made from the sciatic notch to the knee. Following this initial inci-
sion, another small incision was made through the hamstring muscles to allow access to the tib-
ial nerve. The tibial nerve was then separated from the peroneal and sural nerve branches at
the area of the popliteal fossa. Using an 8–0 sterile silk suture, knots were made around the
distal and proximal ends of the tibial nerve, separated by ~5 mm. A3 mm piece of nerve
between the two knots was then removed and the proximal end of the tibial nerve was sutured
to the biceps femoris to prevent re-innervation. After denervation, the incisions made in the
muscle and skin were sutured together and glued with vet-bond. Following the surgery, mice
were given 0.1 ml Buprenorphine (0.03 mg/ml) for analgesia and monitored until they were
ambulatory. Mice were brought back to the laboratory 7 or 14 days post-surgery.
Ex vivomuscle preparation and contractility measurements. The soleus muscle from
the left hindlimb of an anesthetized mouse was dissected free and studied using an ex vivo
preparation, similar to that described previously [30–32]. Following excision, the muscle was
mounted in an organ bath containing a Krebs-Ringer buffer (pH 7.3) with 115 mMNaCl,
5.9 mM KCl, 1.2 mMMgCl2, 1.2 mM NaH2PO4, 1.2 mMNa2SO4, 2.5 mM CaCl2, 25 mM
NaHCO3 and 10 mM glucose, which was equilibrated with 95% O2-5% CO2 gas and main-
tained at 25°C via a circulating water system. The distal tendon was attached by a silk suture
and secured to a fixed support, and the proximal tendon was attached to the lever arm of a ser-
vomotor system (300B; Aurora Scientific Inc., Aurora, ON, Canada). Optimal muscle length
(Lo) in the organ bath was set with a series of twitch stimulations (0.2 ms pulse at 30 V). Ex
vivomuscle length was then measured from the proximal to the distal myotendinous junctions
using a digital caliper. Three minutes after Lo was determined, the muscle performed a final
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twitch contraction followed by a force-frequency protocol that included five isometric contrac-
tions (900 ms train of 0.2 ms pulses at 10, 40, 80, 100 and 120 Hz), all separated with a 3 min
rest period. For analysis, the final twitch was recorded as peak isometric twitch force (Pt),
whereas the highest recorded force during the force-frequency protocol was defined as peak
isometric tetanic force (Po).
Force-frequency relationships were modeled with the following equation: f(x) = min + (max
−min) / [1 + (x/ EC50)
n], where x is the stimulation frequency, min and max are the smallest
(i.e., twitch) and largest (i.e., peak tetanic) respective estimated forces, EC50 is the stimulation
frequency at which half the amplitude of force (max −min) is reached and n, the Hill coeffi-
cient, characterizes the slope of the curve at its midpoint.
After Po was determined, the load clamp technique was used to determine velocity of con-
traction as previously described [33, 34]. In brief, the muscle length was set at Lo and activated
at various percentages of Po (10, 20, 30, 40, 60, 70, 80 and 90%) using the stimulation frequency
that corresponded to Po for a 500 ms train. Once the muscle could overcome the set load
(clamped at 10–90% of Po), the muscle concentrically contracted and the distance the servomo-
tor level arm moved was recorded. The contraction velocity for each % load of Po was then
computed and converted from millimeters per second (mm/s) to a normalized measurement
of fiber lengths per second (fl/s) using a ratio of intact fiber length to muscle length of 0.69
[35]. Using a customMATLAB (Natick, MA) program, a force-velocity curve was generated
using the hyperbolic Hill equation and the maximum unloaded velocity (Vmax) was determined
by extrapolation to the zero load of the force-velocity relationship. From the force and velocity
data, a force-power curve was constructed in MATLAB (by fitting the data to a 5th degree poly-
nomial curve) and peak power (Pmax) and the percentage of Po at which Pmax occurred (% Po at
Pmax) were calculated.
Following the force-velocity protocol, the soleus muscle was removed, trimmed, weighed
and stored at −80°C for later analysis. Physiological cross-sectional area (PCSA) was computed
using the average density of skeletal muscle: PCSA (cm2) = muscle mass (g)/[Lo (cm)1.06
(g/cm3)] [36]. To attain relative force and power values, all absolute values were normalized to
PCSA (cm2).
Histology. In mice that were not used for the ex vivo physiology experiments, the soleus
muscles were excised, embedded in a tissue freezing medium and immediately frozen in
2-methylbutane cooled in liquid nitrogen. Transverse, serial sections at 10 μmwere cut through
the mid-belly of the soleus muscle using a cryostat (Leica CM3050S, Nussloch, Germany). Sec-
tions were then processed for hematoxylin and eosin staining, dehydrated, mounted and visu-
alized at 10X with a Nikon Eclipse E400 microscope (Nikon, Tokyo, Japan) as previously
described [33]. The CSA of approximately 300 fibers per muscle was calculated using ImageJ
analysis software (National Institutes of Health, Bethesda, MD, USA).
Western blotting. Left soleus muscles were homogenized in an ice-cold RIPA lysis and
extraction buffer (Thermo Scientific, Rockford, IL) supplemented with a protease inhibitor
cocktail (Thermo Scientific). Total protein content was quantified with a bicinchoninic acid
(BCA) assay (Thermo Scientific) using bovine serum albumin (BSA) as a standard. A portion
of the muscle homogenate was then diluted in a loading buffer and heated for 4 min. Equal
amounts of protein (25 μg) were loaded onto a 10% SDS polyacrylamide gel and separated
according to molecular weight (100 V for 120 min). The proteins were then transferred to a
PDVF membrane using a semi-dry transfer system at 15 V for 30 min (Bio-Rad Laboratories,
Hercules, CA). Membranes were allowed to dry overnight and then blocked in 5% nonfat dried
milk (w/v) dissolved in tris-buffered saline with 0.1% Tween-20 (TBS-T) for 1 hour at room
temperature. Following the block, the membranes were probed with an anti-MuRF1 (1:250;
#32920, Santa Cruz), anti-ubiquitin (1:2000; #3933, Cell Signaling), anti-19S Rpt1/S7 subunit
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(referred to as 19S in the present study) (1:1000; #PW9400, Enzo Life Sciences), anti-α7
(1:1000; #PW8110, Enzo Life Sciences), anti-β5 (1:1000; #PA1-977, Thermo Scientific), anti-
GAPDH (1:5000; #3683, Cell Signaling) or an anti-α-tubulin (1:2000, #2144, Cell Signaling)
primary antibody diluted in 0.2% nonfat dried milk dissolved in TBS-T for 2 h at room temper-
ature on an orbital shaker. Following incubation in the primary antibodies, membranes were
washed with TBS-T (3×5 min) and then probed with the appropriate secondary antibody (goat
anti-rabbit IgG, 1:10000; Santa Cruz or goat anti-mouse IgG, 1:10000; Thermo Scientific) in
5% nonfat dried milk dissolved in TBS-T for 1 h at room temperature with shaking and washed
as previously stated. Membranes were then treated with an enhanced chemiluminescent solu-
tion (Thermo Scientific) prior to detection using a BioRad ChemiDoc XRS imaging station
(Bio-Rad Laboratories) and analyzed by densitometry using QuantityOne software (Bio-Rad
Laboratories).
To note, GAPDH and α-tubulin were initially selected to serve as loading controls; however,
were not used because they significantly changed as a result of denervation (See Results). Thus,
to ensure protein load was similar between samples, all membranes were stained with Ponceau
S before blocking or Coomassie Blue after imaging.
Proteasome proteolytic activity. Because β5 performs chymotrypsin-like activity we spe-
cifically determined its proteolytic activity by measuring degradation of fluorogenic peptide
substrates as previously described [37]. In brief, 10 μg of the muscle homogenate (prepared as
described inWestern blotting with the exception of the protease inhibitor cocktail) was incu-
bated either with or without the proteasome inhibitor MG132 (0.2 mM) (Peptides Interna-
tional, Louisville, KY) in 100 μl of a 50 mM Tris buffer (pH 7.8) for 30 min at 37°C. After
incubation, 100 μL of a fluorogenic peptide mixture containing 75 μM of LLVY-AMC (Protea-
some Substrate III, Fluorogenic, Millipore, Billerica, MA) dissolved in a 40 mM Tris (pH 7.5)
buffer supplemented with 20 mM KCL, 10 mMMgCl2, and 0.5 mM ATP was added to each
sample. To note, the fluorogenic peptide LLVY-AMC is used to model chymotrypsin-like
activity. Fluorescence was measured at 37°C in a Synergy™HTXMulti-Mode Microplate
Reader (BioTek, Winooski, VT) at a wavelength of 360/40 nm (excitation), 460/40 nm (emis-
sion) and a gain of 70 for 2 h at 5 min intervals. Chymotrypsin-like activity was determined
by comparing peptide fluorescence from samples with fluorescence of a standard curve of
7-amino-4-methylcoumarin (AMC, Sigma-Aldrich, St. Louis, MO). The difference between
assays with or without MG132 represented the proteasome-specific chymotrypsin-like activity
and was used for analysis.
Determination of contractile protein content (Silver staining). Protein content of myo-
sin heavy chain (MHC) and actin were estimated using a gel silver staining kit (Bio-Rad) as
previously described [38]. Briefly, equal amounts of protein (2 μg) were loaded onto an 8%
SDS polyacrylamide gel and separated according to molecular weight (100 V for 100 min). Fol-
lowing electrophoresis, gels were fixed for 20 min and decanted with deionized distilled water
for 20 min (2×10 min). Gels were then silver stained for 16–21 min, transferred into a 5% acetic
acid solution for 15 min to stop the reaction and rinsed with deionized distilled water for 20
min (2×10 min). The stained gels were imaged using a BioRad GS-800 imager (Bio-Rad) and
analyzed by densitometry using QuantityOne software (Bio-Rad). Specifically, content within
each gel lane was determined, which provided an estimation of the relative amount of MHC
and actin per sample.
Statistics analysis
An independent t-test or one-way ANOVA was used to determine differences between groups
when two (control vs. 14 day) or three (control vs. 7 day vs. 14 day) independent variables were
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selected, respectively. To assess changes between groups across force-frequency, force-velocity
and force-power curves, all data (group × Hz or % Po) were entered into a two-way repeated
measures ANOVA. A Fisher’s least significant difference (LSD) post hoc test was performed in
the event of a significant ANOVA. An α-level of0.05 was used for all analyses. Values are
presented in mean±SEM. All statistical testing was performed using SigmaPlot version 11.0
(Systat Software, San Jose, CA).
Results
Activation of the ubiquitin-proteasome system
To assess how the ubiquitin-proteasome system responded to denervation, we used Western
blot analysis to determine content of several key proteins implicated in this pathway (Figs 1
and 2). The first protein assessed was the E3 ligase MuRF1 because it can interact with several
key sarcomeric proteins. As previously reported, MuRF1 content was relatively low under basal
conditions, but increased as a result of denervation [15]. By 7 days post-denervation, MuRF1
content was elevated 73% (p = 0.003; Fig 1A) and was accompanied by a 42% (p = 0.008; Fig 2)
increase in total ubiquitin content. At day 14, MuRF1 content returned to baseline (p = 0.19)
while total ubiquitin content remained elevated (55%, p = 0.001). At both 7 and 14 days post-
denervation, most of the ubiquitinated proteins were observed just above 25 kDa and between
75 to150 kDa.
Next, we assessed different components of the 26S proteasome by measuring a subunit of
the 19s regulatory complex and two subunits of the 20S catalytic core, α7 and β5 (Fig 1B–1D).
The changes in proteasome content were similar to that of MuRF1 and ubiquitin at day 7.
Specifically, 19S, α7 and β5 content increased 79% (p = 0.004), 34% (p = 0.022) and 36%
(p = 0.012), respectively. By day 14, 19S, α7 and β5 content decreased and did not differ from
control muscle (p0.32). As expected, chymotrypsin-like activity of the proteasome was back to
baseline 14 days post-denervation (control: 17.82±1.91 vs. 14 day: 23.27±3.13 pmolmg-1min-1,
p = 0.19), comparable to that of β5 content.
Skeletal muscle atrophy and contractile function
Soleus wet weight and fiber CSA were reduced by 28% and 41% by day 14 (p0.001; Fig 3),
respectively. Both of which indicate myofibrillar protein content declined following denerva-
tion. Therefore, we sought to determine if these reductions were due to a preferential loss of
MHC or actin by assessing silver stained gels that were loaded with equal amounts of protein
(2 μg). Despite the loss of muscle wet weight and fiber CSA (Fig 3), the relative concentration
of MHC, actin and MHC/actin remained similar between the control and denervated muscle
(p0.72; Fig 4). This observation suggests that MHC and actin content were lost at comparable
rates when assessed at 7 and 14 days post-denervation.
Due to the loss of muscle wet weight and fiber CSA observed at day 14 (Fig 4), it was appar-
ent contractile function would also be reduced, particularly when expressed in absolute terms
(i.e., not relative to PCSA). As hypothesized, absolute Po decreased 19% (p = 0.021; Fig 5A and
Table 1) while relative Po remained unchanged (p = 0.80; Fig 5B and Table 1).
Unexpectedly, Pt did not mimic that of Po, as absolute and relative Pt both increased in the
denervated muscle (74%, p = 0.001 and 120%, p0.001; Fig 5A, 5B and Table 1). To further
assess these changes, time to Pt (TPT) and one-half relaxation time (RT1/2) were also analyzed
(Table 1). As with Pt, both increased at day 14 (~60% p0.001), which indicates a slowing of
the contraction after denervation.
Additionally, there was a leftward shift in the force-frequency curves following denervation,
which was accompanied by reductions in EC50 and the Hill coefficient (p0.001; Fig 5A, 5B and
Muscle Quality and the Ubiquitin-Proteasome System
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Fig 1. Protein content of (A) MuRF1, (B) 19S, (C) α7 and (D) β5 in control, 7 day or 14 day soleusmuscle.Content of each protein was
determined usingWestern blot analysis, normalized to the control muscle and set at 1.0. Pictured above the graphs are representative Western
blots for each protein with arrows indicating molecular weight standards. All lanes were loaded with an equal amount of total protein (25 μg). Control
was innervated muscle, 7 day was denervated for 7 days and 14 day was denervated for 14 days. Sample size per group, n = 5–7. Values are
mean±SEM. *Significantly different from control (p0.05). #Significantly different from 7 day (p0.05). A.U., arbitrary units.
doi:10.1371/journal.pone.0160839.g001
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Fig 2. Total ubiquitin content in control, 7 day or 14 day soleusmuscle.Content of each protein was
determined usingWestern blot analysis, normalized to the control muscle and set at 1.0. Pictured above the
graph is a representative Western blot with arrows indicating molecular weight standards. The stained
membrane is a representative section (above ~37 kDa) of a Coomassie Blue stained membrane. All lanes
were loaded with an equal amount of total protein (25 μg). Control was innervated muscle, 7 day was
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denervated for 7 days and 14 day was denervated for 14 days. Sample size per group, n = 5–7. Values are
mean±SEM. *Significantly different from control (p0.05). A.U., arbitrary units.
doi:10.1371/journal.pone.0160839.g002
Fig 3. Fiber (A) distribution and (B) mean cross-sectional area (CSA) in control and 14 day soleus muscle. Pictured above
the graphs are representative hematoxylin and eosin stains. Control was innervated muscle and 14 day was denervated for 14
days. Sample size per group, n = 6–7. Values are mean±SEM. *Significantly different from control (p0.05).
doi:10.1371/journal.pone.0160839.g003
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Fig 4. Protein content of (A) myosin heavy chain: MHC, (B) actin and (C) MHC/actin in control, 7 day or 14 day soleus
muscle. Content of each protein was determined using gel silver staining, normalized to the control muscle and set at 1.0. Pictured
to the left of the graphs is a representative silver stained gel with arrows indicating molecular weight standards. All lanes were
loaded with an equal amount of total protein (2 μg). Therefore, these results depict that although denervation reduced fiber size (Fig
3), the relative concentration of MHC, actin and MHC/actin remained similar between the control and denervated muscle. Control
Muscle Quality and the Ubiquitin-Proteasome System
PLOSONE | DOI:10.1371/journal.pone.0160839 August 11, 2016 10 / 18
Table 1). Upon further analysis of the force-frequency curves, it was also apparent denervation
affected absolute and relative force at several other stimulation frequencies, besides those that
elicited Pt and Po. Absolute force at 10 Hz increased (p<0.001) while force at 80, 100 and 120 Hz
(p0.016) decreased 14 days post-denervation. Moreover, relative force increased at 10 and 40
Hz (p0.037) but did not differ from control muscle at higher frequencies (p0.42).
was innervated muscle, 7 day was denervated for 7 days and 14 day was denervated for 14 days. Sample size per group, n = 5–7.
Values are mean±SEM. A.U., arbitrary units.
doi:10.1371/journal.pone.0160839.g004
Fig 5. Ex vivo (A) absolute force, (B) relative force, (C) absolute power and (D) relative power in control and 14 day soleusmuscle.Control was
innervated muscle and 14 day was denervated for 14 days. Sample size per group, n = 6–8. Values are mean±SEM. *Significantly different from control
(p0.05). Pt, peak isometric twitch force.
doi:10.1371/journal.pone.0160839.g005
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Muscle power is the product of force and contraction velocity. Despite the changes observed
in the force-frequency curves, denervation had no effect on Vmax (p = 0.84, Table 1) or the
force-velocity relationship (p = 0.99, S1 Fig). Peak power (Pmax) occurred at ~26% of Po and
was not different 14 days post-denervation (p = 0.77; Fig 5C, 5D and Table 1). However, abso-
lute Pmax decreased 25% (p = 0.050), comparable to the 19% reduction in absolute Po previ-
ously stated. A similar reduction was also observed at 20, 30 and 40% of absolute Po 14 days
post-denervation (p0.029). As with relative Po, denervation did not alter relative Pmax
(p = 0.44) or any other relative % Po on the force-power curve (p = 0.98).
GAPDH and α-tubulin protein content
Content of GAPDH did not differ from control muscle 7 days following denervation (p0.14);
however, decreased 20% by day 14 (p = 0.001, Fig 6A). Contrary to GAPDH, content of α-
tubulin dramatically increased 7 days post-denervation and remained elevated through day 14
(~84%, p0.001; Fig 6B). It is worth noting that GAPDH and α-tubulin are common house-
keeping proteins used by many as loading controls. However, as we and others report [39–41],
these proteins are significantly influenced by denervation and therefore, if set as loading con-
trols, caution should be used.
Discussion
Skeletal muscle atrophy is primarily due to the loss of myofibrillar proteins and is a hallmark
outcome of many clinical conditions and chronic diseases. The increase in proteolysis is largely
Table 1. Soleusmuscle characteristics and ex vivo contractile parameters.
Control Denervated
Muscle weight (mg) 10.76±0.51 7.72±0.25*
Histological CSA (μm2) 2040.88±139.86 1210.32±39.66*
Muscle length (mm) 10.82±0.33 10.60±0.44
PCSA (mm2) 0.92±0.08 0.71±0.02*
Absolute Pt (mN) 32.59±3.64 56.73±4.56*
Absolute Po (mN) 215.28±15.57 173.68±5.83*
Relative Pt (N cm
-2) 3.65±0.41 8.01±0.61*
Relative Po (N cm
-2) 24.10±1.94 24.69±1.22
TPT (ms) 36.43±1.88 56.71±1.60*
RT1/2 (ms) 40.29±1.25 66.14±5.20*
EC50 (Hz) 26.20±1.32 11.04±0.57*
Hill coefficient 2.48±0.12 1.89±0.06*
Vmax (fl/s) 4.40±0.26 4.34±0.20
Absolute Pmax (mW) 0.57±0.05 0.43±0.04*
Relative Pmax (mW cm
-2) 63.93±3.26 58.96±5.03
%Po at Pmax (%) 26.33±1.05 26.71±0.71
Values are means±SEM. Sample size per group, n = 19–20 for muscle weight. For all other variables,
n = 6–8. The control group consisted of soleus muscle that was innervated, while the denervated group
included soleus muscle that was denervated for 14 days. CSA, cross-sectional area; PCSA, physiological
cross-sectional area; Pt, peak isometric twitch force; Po, peak isometric tetanic force; TPT, time to Pt; RT1/2,
one-half Pt relaxation time; EC50, frequency at which 50% Po was developed; Hill coefficient, slope
coefficient of the force-frequency curve at its midpoint; Vmax, maximum unloaded velocity; Pmax, peak power.
* Significantly different from control (p0.05).
doi:10.1371/journal.pone.0160839.t001
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attributed to the ubiquitin-proteasome system, the primary pathway responsible for degrading
the contractile apparatus. Despite the correlative relationship between the ubiquitin-protea-
some system and skeletal muscle quantity, it is unclear how muscle quality is affected soon
after an episode of increased proteolysis mediated by this pathway. Therefore, we denervated
mouse soleus muscle for up to 14 days and assessed content of the ubiquitin-proteasome sys-
tem, in addition to ex vivo whole muscle contractility. Here, we report content of several key
proteins within the ubiquitin-proteasome system temporarily increased following denervation
and as a result, reduced skeletal muscle size. These changes were accompanied by reductions in
absolute Po and Pmax, which were offset when expressed relative to PCSA. However, contrary
to Po, absolute and relative Pt increased as a result of denervation. Taken together, these data
represent two key findings. First, activation of the ubiquitin-proteasome system is associated
with reductions in skeletal muscle quantity rather than quality. Second, despite the loss of con-
tractile proteins, short-term denervation increased force at submaximal stimulation frequen-
cies, which suggests Ca2+ handling was enhanced possibly to compensate for the loss of neural
activity.
Denervation-induced muscle atrophy models are known to increase several components of
the ubiquitin-proteasome system, including E3 ligases, content of ubiquitinated proteins and
several subunits of the 26S proteasome. Upregulation of the ubiquitin-proteasome system has
been reported to increase as early as 2–3 days post-denervation [20–22] and remain elevated
up to 14 days [22, 23]. Due to the complexity of this pathway and the various E3 ligases and
proteasome subunits present in skeletal muscle, many of these studies assessed specific parts of
Fig 6. Protein content of (A) GAPDH and (B) α-tubulin in control, 7 day or 14 day soleusmuscle.Content of each protein was determined using
Western blot analysis, normalized to the control muscle and set at 1.0. Pictured above the graphs are representative Western blots for each protein with
arrows indicating molecular weight standards. All lanes were loaded with an equal amount of total protein (25 μg). Control was innervated muscle, 7 day
was denervated for 7 days and 14 day was denervated for 14 days. Sample size per group, n = 5–7. Values are mean±SEM. *Significantly different from
control (p0.05). #Significantly different from 7 day (p0.05). A.U., arbitrary units.
doi:10.1371/journal.pone.0160839.g006
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the ubiquitin-proteasome system rather than it as a whole. However, it is apparent that these
components (i.e., E3 ligases and proteasome subunits) are regulated in a coordinated response
to mediate skeletal muscle proteolysis [21] and are controlled by similar transcription factors
[8, 20]. Our analysis included key proteins from several different components of the ubiquitin-
proteasome system: the E3 ligase MuRF1, total ubiquitin content and three subunits from dif-
ferent rings of the 26S proteasome (i.e., 19S, α7 and β5). As reported by others [20–23], protein
content (or mRNA expression) of the ubiquitin-proteasome system significantly increased fol-
lowing denervation. Specifically, MuRF1, ubiquitin, 19S, α7 and β5 content were elevated 7
days post-denervation and returned to control levels by day 14, with the exception of ubiquitin.
Other E3 ligases like NEDD4, which are not associated with sarcomeric proteins, have been
found to be more persistent in denervated muscle [22, 28, 39] and may contribute to the pres-
ence of these ubiquitinated proteins beyond day 7, after MuRF1 and proteasome content have
declined.
The temporary increase in MuRF1, 19S, α7 and β5 content was associated with reductions
in soleus muscle wet weight and fiber CSA after 14 days of denervation. Loss of muscle size is
thought to be primarily due to the proteolysis of MHC and actin by the ubiquitin-proteasome
system [9]. Importantly, when loading equal amounts of protein (2 ug), the ratio of MHC to
actin did not change following 7 or 14 days of denervation, illustrating MHC and actin were
degraded at similar rates. Comparable results have previously been reported in mouse gastroc-
nemius muscle after 10 days of denervation [15]. In support of our MHC to actin ratio, abso-
lute Po and Pmax were reduced while relative Po and Pmax were unaffected, which suggests the
muscle’s intrinsic ability to generate force was not influenced at day 14. Furthermore, denerva-
tion did not significantly alter Vmax indicating the decrease in Pmax was primarily due to Po, or
more accurately, degradation of the myofibrillar proteins and thus loss of fiber CSA. These
contractile observations (i.e., Po, Pmax and Vmax) confirm that of Greising et al. [27], who used
tibial nerve transection and assessed soleus muscle from ovariectomized female mice following
14 days of denervation.
However, at later time points, others have shown the muscle’s intrinsic ability to generate
force inevitability declines [25, 26]. For instance, Agbulut et al. [25] demonstrated that after
one month of denervation, mouse soleus muscle exhibits marked reductions in Vmax and rela-
tive Po and Pmax when compared to innervated control muscle. Taken together, the present
findings and that of others [25, 26] suggest muscle quality is maintained soon after the ubiqui-
tin-proteasome system has been activated, yet in the ensuing weeks muscle quality steadily
declines. We propose that the reductions observed in muscle quality after extended periods of
denervation (e.g.,one month) are due to factors other than the ubiquitin-proteasome system.
Although these factors were not determined in the present study, others have shown denerva-
tion eventually affects muscle quality by reducing the fraction of CSA occupied by the contrac-
tile proteins [42–44] and through decreasing the fibers’ sensitivity to Ca2+ [45].
In addition to these findings, the fact that both absolute and relative submaximal force (10
Hz and40 Hz, respectively) increased following denervation indicates Ca2+ handling was
enhanced. When specifically assessing the twitch contraction, we observed an overall improve-
ment of 74% in absolute force and 120% in relative force, which was accompanied by a 60%
increase in TPT and RT1/2. Although these changes (i.e., twitch parameters) have not been
reported in mouse soleus muscle at this specific time point, they are consistent with that seen
in rat soleus muscle following 7 days of denervation [46]. These results suggest Ca2+ kinetics,
such as Ca2+ release, diffusion and binding, were influenced shortly after skeletal muscle dener-
vation [47]. In support of this, in the aforementioned rat soleus muscle, sarcoplasmic reticulum
(SR) Ca2+ release was markedly elevated after 7 days of denervation and correlated with the
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slowing of the twitch contraction. With more time to develop force and Ca2+ available to bind
with troponin C, Pt will ultimately increase as we and other have observed [26, 46].
Notably, these changes occurred during a period of significant proteolysis, as seen by the
loss of both muscle mass and CSA, which suggests the excitation-contraction (EC) coupling
pathway may undergo remodeling following denervation [48]. Some important features within
the EC coupling pathway of denervated rodent muscle that could influence Ca2+ handling,
include acetylcholine receptor expression, density and sensitivity [49, 50], dihydropyridine
receptor expression [51–53] and SR Ca2+ loading capacity [46, 47]. Interestingly, similar obser-
vations (i.e., upregulation of the acetylcholine and dihydropyridine receptors) have been
reported in the days following eccentric contraction-induced injury when EC coupling failure
is pervasive [30, 54, 55]. These changes may reflect a compensatory mechanism to counteract
the loss in voltage-induced SR Ca2+ release that occurs after eccentric contractions (i.e., 0–5
days post-injury) or denervation in skeletal muscle. However, Pt has been shown to progres-
sively decline following extended periods of denervation, despite TPT and RT1/2 remaining
prolonged [25, 26]. We propose that the changes observed in Ca2+ handling are negated by the
persistent loss of the myofibrillar apparatus and/or eventual reduction in the muscle’s quality.
In closing, we demonstrate that several key proteins of the ubiquitin-proteasome system
including MuRF1, 19S, α7 and β5 were all upregulated in mouse soleus muscle after denerva-
tion. Content of these proteins increased in a coordinated fashion and were only temporally
affected by denervation. These changes were associated with reductions in muscle size and max-
imal force, but not muscle quality, at least at 14 days post-denervation. In contrast, submaximal
force was improved despite the loss of MHC and actin, which suggests Ca2+ handling was
enhanced. Taken together, our results demonstrate the ubiquitin-proteasome system is a fine-
tuned proteolytic pathway, which upon activation primarily impairs maximal force by reducing
skeletal muscle size, rather than its intrinsic ability to generate force. In addition, we also suggest
the EC coupling pathway undergoes remodeling in concert to the proteolysis that occurs shortly
following denervation, possibly to compensate for the loss in voltage-induced SR Ca2+ release.
Supporting Information
S1 Fig. Ex vivo force-velocity relationship in control and 14 day soleus muscle. Control was
innervated muscle and 14 day was denervated for 14 days. Sample size per group, n = 6–8. Val-
ues are mean±SEM.
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